033270 — Korea United Pharm Income Statement
0.000.00%
- KR₩348bn
- KR₩229bn
- KR₩279bn
- 93
- 77
- 64
- 94
Annual income statement for Korea United Pharm, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 221,311 | 215,950 | 221,040 | 262,522 | 278,943 |
Cost of Revenue | |||||
Gross Profit | 128,588 | 125,192 | 122,660 | 145,288 | 158,977 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 186,831 | 175,824 | 187,815 | 214,309 | 224,641 |
Operating Profit | 34,479 | 40,126 | 33,225 | 48,213 | 54,302 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 38,534 | 35,650 | 39,483 | 53,425 | 60,084 |
Provision for Income Taxes | |||||
Net Income After Taxes | 30,916 | 26,613 | 28,649 | 45,275 | 48,262 |
Net Income Before Extraordinary Items | |||||
Net Income | 30,916 | 26,613 | 28,649 | 45,275 | 48,262 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 30,916 | 26,613 | 28,649 | 45,275 | 48,262 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2,092 | 1,789 | 1,913 | 3,025 | 3,313 |
Dividends per Share |